AR112604A1 - Receptores de células t, e inmunoterapia usando los mismos - Google Patents

Receptores de células t, e inmunoterapia usando los mismos

Info

Publication number
AR112604A1
AR112604A1 ARP180101832A AR112604A1 AR 112604 A1 AR112604 A1 AR 112604A1 AR P180101832 A ARP180101832 A AR P180101832A AR 112604 A1 AR112604 A1 AR 112604A1
Authority
AR
Argentina
Prior art keywords
antigen
spink2
recognizing constructs
taa
tcr
Prior art date
Application number
Other languages
English (en)
Spanish (es)
Inventor
Wagner Claudia Dr
Maurer Dominik Dr
Bunk Sebastian Dr
Alten Leonie Dr
Original Assignee
Immatics Biotechnologies Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immatics Biotechnologies Gmbh filed Critical Immatics Biotechnologies Gmbh
Publication of AR112604A1 publication Critical patent/AR112604A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8135—Kazal type inhibitors, e.g. pancreatic secretory inhibitor, ovomucoid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/38—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against protease inhibitors of peptide structure
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C12N2015/8518—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic expressing industrially exogenous proteins, e.g. for pharmaceutical use, human insulin, blood factors, immunoglobulins, pseudoparticles

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Endocrinology (AREA)
  • Plant Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
ARP180101832 2017-06-30 2018-06-29 Receptores de células t, e inmunoterapia usando los mismos AR112604A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102017114737.3A DE102017114737A1 (de) 2017-06-30 2017-06-30 Neue T-Zellrezeptoren und deren Verwendung in Immuntherapie

Publications (1)

Publication Number Publication Date
AR112604A1 true AR112604A1 (es) 2019-11-20

Family

ID=64662173

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP180101832 AR112604A1 (es) 2017-06-30 2018-06-29 Receptores de células t, e inmunoterapia usando los mismos

Country Status (22)

Country Link
US (5) US10590194B2 (enExample)
EP (1) EP3645573B1 (enExample)
JP (1) JP7235316B2 (enExample)
KR (1) KR20200023288A (enExample)
CN (1) CN110753705A (enExample)
AR (1) AR112604A1 (enExample)
AU (1) AU2018293322A1 (enExample)
BR (1) BR112019025323A2 (enExample)
CA (1) CA3067757A1 (enExample)
CL (1) CL2019003885A1 (enExample)
CO (1) CO2020000357A2 (enExample)
CR (1) CR20190594A (enExample)
DE (1) DE102017114737A1 (enExample)
IL (1) IL271751A (enExample)
MA (1) MA49503A (enExample)
MX (1) MX2019015742A (enExample)
MY (1) MY205262A (enExample)
PE (1) PE20200337A1 (enExample)
PH (1) PH12019502847A1 (enExample)
SG (1) SG11201911437VA (enExample)
TW (1) TWI727182B (enExample)
WO (1) WO2019002444A1 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY196837A (en) 2015-12-11 2023-05-03 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against various cancers
DE102018108612A1 (de) 2018-03-21 2019-09-26 Immatics US, Inc. Verfahren zur erhöhung der persistenz von adoptiv infundierten t-zellen
US20200297768A1 (en) 2019-03-19 2020-09-24 Immatics US, Inc. Cd28 t cell cultures, compositions, and methods of using thereof
DE102019108125B4 (de) 2019-03-28 2022-02-03 Immatics US, Inc. Cd28 t-zellkulturen, zusammensetzungen und verfahren zu deren verwendung
KR20220029584A (ko) 2019-05-27 2022-03-08 이매틱스 유에스 인코포레이티드 바이러스 벡터 및 입양 세포 요법에서 그 사용
US20210032370A1 (en) 2019-08-02 2021-02-04 Immatics Biotechnologies Gmbh Recruiting agent further binding an mhc molecule
CN112442119B (zh) * 2019-09-05 2023-02-24 香雪生命科学技术（广东）有限公司 一种识别ssx2的高亲和力t细胞受体
JP2023515131A (ja) 2020-02-24 2023-04-12 イマティクス ユーエス，アイエヌシー． がんおよび関連する悪性腫瘍の治療のためにｔ細胞を増殖させる方法
DE102020111571A1 (de) 2020-03-11 2021-09-16 Immatics US, Inc. Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren
WO2022040631A1 (en) 2020-08-21 2022-02-24 Immatics US, Inc. Methods for isolating cd8+ selected t cells
CR20230295A (es) 2020-12-31 2023-07-27 Immatics Us Inc Polipéptidos cd8, composiciones y métodos de uso de estos
DE102021100038A1 (de) 2020-12-31 2022-06-30 Immatics US, Inc. Modifizierte cd8-polypeptide, zusammensetzungen und verfahren zu deren verwendung
KR20240004937A (ko) 2021-05-05 2024-01-11 이매틱스 바이오테크놀로지스 게엠베하 Bma031 항원 결합 폴리펩타이드
US20230089392A1 (en) 2021-09-20 2023-03-23 Immatics US, Inc. Monocyte depletion of t cells populations for t-cell therapy
US20230142468A1 (en) 2021-11-08 2023-05-11 Immatics US, Inc. Methods for generating cell spheroids
US20230348561A1 (en) 2022-04-28 2023-11-02 Immatics US, Inc. Dominant negative tgfbeta receptor polypeptides, cd8 polypeptides, cells, compositions, and methods of using thereof
WO2023212655A1 (en) 2022-04-28 2023-11-02 Immatics US, Inc. Il-12 polypeptides, il-15 polypeptides, il-18 polypeptides, cd8 polypeptides, compositions, and methods of using thereof
KR20250018168A (ko) 2022-04-28 2025-02-04 이매틱스 유에스 인코포레이티드 막-결합된 il-15, cd8 폴리펩티드, 세포, 조성물, 및 이의 사용 방법
EP4519418A1 (en) 2022-05-05 2025-03-12 Immatics US, Inc. Methods for improving t cell efficacy
AU2024309123A1 (en) * 2023-06-28 2026-01-15 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services T cell receptors targeting ras with g12d, g12r, or g12v mutation
US20250134931A1 (en) 2023-11-01 2025-05-01 Immatics US, Inc. Membrane-bound il-15, cd8 polypeptides, cells, compositions, and methods of using thereof

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
ES2246502T3 (es) 1990-08-29 2006-02-16 Genpharm International, Inc. Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
US5714352A (en) 1996-03-20 1998-02-03 Xenotech Incorporated Directed switch-mediated DNA recombination
WO2000006732A2 (en) * 1998-07-31 2000-02-10 Diagnostic Products Corporation Polynucleotide encoding an autoantigen associated with endometriosis
WO2001058479A1 (en) 2000-02-08 2001-08-16 The Penn State Research Foundation Immunotherapy using interleukin 13 receptor subunit alpha 2
GB0525999D0 (en) * 2005-12-21 2006-02-01 Ares Trading Sa Novel members of the kazal family of serine protease inhibitors
KR101773690B1 (ko) * 2007-03-05 2017-08-31 인터내셔널 인스티튜트 오브 캔서 이무놀로지 인코퍼레이티드 암 항원 특이적 ｔ 세포의 수용체 유전자 및 그것에 따라 코드되는 펩티드 및 이들의 사용
CA2881431C (en) 2012-08-08 2021-10-19 Daiichi Sankyo Company, Limited Peptide library and use thereof
CN110511960B (zh) * 2013-07-15 2023-05-23 美国卫生和人力服务部 抗人乳头瘤病毒16 e6 t细胞受体
GB201314404D0 (en) * 2013-08-12 2013-09-25 Immunocore Ltd T Cell Receptors
RU2739500C2 (ru) * 2014-11-05 2020-12-25 Дженентек, Инк. Способы получения двуцепочечных белков в бактериях
EP3156067A1 (en) * 2015-10-16 2017-04-19 Max-Delbrück-Centrum Für Molekulare Medizin High avidity hpv t-cell receptors
GB201520567D0 (en) * 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520597D0 (en) * 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201521894D0 (en) * 2015-12-11 2016-01-27 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against various cancers

Also Published As

Publication number Publication date
US20200140540A1 (en) 2020-05-07
PH12019502847A1 (en) 2020-10-26
WO2019002444A9 (en) 2019-03-14
JP2020529830A (ja) 2020-10-15
CA3067757A1 (en) 2019-01-03
JP7235316B2 (ja) 2023-03-08
PE20200337A1 (es) 2020-02-14
EP3645573B1 (en) 2024-10-16
IL271751A (en) 2020-02-27
MX2019015742A (es) 2020-02-20
US11111294B2 (en) 2021-09-07
EP3645573A1 (en) 2020-05-06
CR20190594A (es) 2020-03-02
CL2019003885A1 (es) 2020-05-29
US20190002556A1 (en) 2019-01-03
WO2019002444A1 (en) 2019-01-03
US20190256590A1 (en) 2019-08-22
MY205262A (en) 2024-10-10
DE102017114737A1 (de) 2019-01-03
KR20200023288A (ko) 2020-03-04
TW201904989A (zh) 2019-02-01
US10590194B2 (en) 2020-03-17
US20210388079A1 (en) 2021-12-16
TWI727182B (zh) 2021-05-11
BR112019025323A2 (pt) 2020-06-23
MA49503A (fr) 2020-05-06
SG11201911437VA (en) 2020-01-30
US10723796B2 (en) 2020-07-28
CN110753705A (zh) 2020-02-04
US20250154246A1 (en) 2025-05-15
CO2020000357A2 (es) 2020-01-31
AU2018293322A1 (en) 2020-01-16

Similar Documents

Publication Publication Date Title
CO2020000357A2 (es) Receptores de células t novedosos, e inmunoterapia usando los mismos
CO2019011688A2 (es) Receptores de linfocitos t e inmunoterapias basadas en el uso de los mismos contra cánceres positivos para prame
MX2020004741A (es) Nuevos receptores de las celulas t modificados geneticamente y terapias immunologicas que emplean los mismos.
MX2019001769A (es) Nuevos receptores de linfocitos t e inmunoterapia basada en el uso de los mismos.
CL2021002997A1 (es) Construcción de reconocimiento de antígeno y su uso para el tratamiento de enfermedades proliferativas y para la detección in vitro de un cáncer (divisional de la solicitud 201901535)
DOP2018000212A (es) Moléculas de unión a bcma y métodos de uso de las mismas
MX2019006724A (es) Nuevos receptores de celulas t y terapia inmunologica que los utiliza.
CL2021001744A1 (es) Péptidos y combinaciones de péptidos para el uso en la inmunoterapia contra el cáncer de próstata y otros tipos de cáncer (divisional de la solicitud no. 201800324)
AR110676A1 (es) Tratamiento del cáncer utilizando receptores de antígenos quiméricos
MX2019006727A (es) Nuevos receptores de celulas t y terapia inmunologica que los utiliza.
PE20200152A1 (es) Receptores de union a antigeno mejorados
MX2017001011A (es) Tratamiento de cancer de usando un receptor quimerico de antigeno anti-bcma.
CL2017003361A1 (es) Nuevos péptidos y combinación de péptidos para usar en inmunoterapia contra el cáncer esofágico y otros cánceres
GT201000148A (es) Anticuerpos antimesotelina y usos de los mismos
CO2022006014A2 (es) Terapia de tumores sólidos cd70+ utilizando linfocitos t genomodificados dirigidos a cd70 referencia cruzada a solicitudes relacionadas
MX2022007833A (es) Nuevos receptores de antigenos quimericos (car) especificos de mesotelina para inmunoterapia de cancer de tumores solidos.
MX2021002225A (es) Composiciones y metodos para la reprogramacion de tcr mediante el uso de proteinas de fusion.
CO2019002229A2 (es) Nuevos receptores de linfocitos t e inmunoterapia basada en el uso de los mismos
AR109345A1 (es) Receptores de linfocitos t e inmunoterapia basada en el uso de los mismos
AR119964A2 (es) Anticuerpos anti-cd123 y conjugados y derivados de estos
EA201992583A1 (ru) Новые t-клеточные рецепторы и иммунотерапия с их применением
EA201992002A1 (ru) Т-клеточные рецепторы и иммунная терапия prame-положительных раковых заболеваний с их применением
EA201990488A1 (ru) Новые t-клеточные рецепторы и иммунотерапия с их применением
AR110682A1 (es) Receptores de células t y terapia inmunológica que los utiliza

Legal Events

Date Code Title Description
FA Abandonment or withdrawal